J Chen1, T Su2, Y Lin3, B Wang3, J Li3, J Pan3, C Chen3. 1. Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, China. junqiangc@163.com. 2. Department of Oncology, Huadu District People's Hospital, Guangzhou, 510000, Guangdong, China. 3. Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, China.
Abstract
PURPOSE: This study was conducted to investigate the efficacy and toxicity of combination treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy with paclitaxel plus different platinum agents in locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: This retrospective study enrolled 242 patients treated with paclitaxel (135 mg/m2) plus platinum regimens. According to the different platinum agents used, patients were classified into: cisplatin 80 mg/m2 (CP), nidaplatinum 80 mg/m2 (NP), lobaplatin 35 mg/m2 (LP), and oxaliplatin 135 mg m2 (OP) groups, and survival and toxicity rates between the four groups were compared. The median overall survival (OS) was 31.1 months. RESULTS: No significant differences were observed among the CP, NP, LP, and OP groups with regard to 3-year survival rates (46.2, 56.4, 45.7, and 29.0%, respectively). A stratified analysis indicated that 3-year survival rates were significantly lower in the OP group. Renal toxicities and gastrointestinal reactions were more frequent in the CP group than in the other three groups. Three-year survival rates were similar among patients receiving 2, 3, or ≥4 cycles of chemotherapy (40.1, 49.5, and 50.8%, respectively). Multivariate analysis indicated that tumor volume and maximum diameter of metastatic lymph nodes might be independent prognostic factors. CONCLUSION: Paclitaxel plus nidaplatinum or lobaplatin is recommended in locally advanced ESCC due to their satisfying therapeutic effects and less toxicity. Tumor volume and maximum diameter of metastatic lymph nodes are independent prognostic factors in ESCC patients receiving IMRT and concurrent chemotherapy.
PURPOSE: This study was conducted to investigate the efficacy and toxicity of combination treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy with paclitaxel plus different platinum agents in locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: This retrospective study enrolled 242 patients treated with paclitaxel (135 mg/m2) plus platinum regimens. According to the different platinum agents used, patients were classified into: cisplatin 80 mg/m2 (CP), nidaplatinum 80 mg/m2 (NP), lobaplatin 35 mg/m2 (LP), and oxaliplatin 135 mg m2 (OP) groups, and survival and toxicity rates between the four groups were compared. The median overall survival (OS) was 31.1 months. RESULTS: No significant differences were observed among the CP, NP, LP, and OP groups with regard to 3-year survival rates (46.2, 56.4, 45.7, and 29.0%, respectively). A stratified analysis indicated that 3-year survival rates were significantly lower in the OP group. Renal toxicities and gastrointestinal reactions were more frequent in the CP group than in the other three groups. Three-year survival rates were similar among patients receiving 2, 3, or ≥4 cycles of chemotherapy (40.1, 49.5, and 50.8%, respectively). Multivariate analysis indicated that tumor volume and maximum diameter of metastatic lymph nodes might be independent prognostic factors. CONCLUSION:Paclitaxel plus nidaplatinum or lobaplatin is recommended in locally advanced ESCC due to their satisfying therapeutic effects and less toxicity. Tumor volume and maximum diameter of metastatic lymph nodes are independent prognostic factors in ESCC patients receiving IMRT and concurrent chemotherapy.
Authors: Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-03 Impact factor: 7.038
Authors: Somnath Mukherjee; Christopher N Hurt; Sarah Gwynne; Andrew Bateman; Simon Gollins; Ganesh Radhakrishna; Maria Hawkins; Jo Canham; Wyn Lewis; Heike I Grabsch; Ricky A Sharma; Wendy Wade; Rhydian Maggs; Bethan Tranter; Ashley Roberts; David Sebag-Montefiore; Timothy Maughan; Gareth Griffiths; Tom Crosby Journal: BMC Cancer Date: 2015-02-12 Impact factor: 4.430
Authors: Xuejiao Liu; Mengqiu Song; Penglei Wang; Ran Zhao; Hanyong Chen; Man Zhang; Yuanyuan Shi; Kangdong Liu; Fangfang Liu; Ran Yang; Enmin Li; Ann M Bode; Zigang Dong; Mee-Hyun Lee Journal: Int J Cancer Date: 2019-04-03 Impact factor: 7.396